Cancer
Malignant Bladder Neoplasm
CI-CAN-00005866Explore in graph →
Top-level346 active trials10 approved drugs25 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00005866Explore in graph →
Clinical trials
1,510 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (179)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06290687 | Partial Cystectomy & Extended Pelvic Lymph Node Dissection With SOC Perioperative Systemic Therapy | withdrawn | Phase 2 | 0 | Case Comprehensive Cancer CenterOTHER | 0 | Sep 24, 2026 | clinicaltrials |
| NCT07414992 | A Study of Radiation Therapy and Cemiplimab With or Without Fianlimab In People With Bladder Cancer | withdrawn | Phase 2 | 0 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT05714826 | Comprehensive Optimization At-time of Radical Cystectomy Intervention(COARC) | withdrawn | N/A | 0 | University of Texas Southwestern Medical CenterOTHER | 0 | May 27, 2026 | clinicaltrials |
| NCT07551544 | ANKTIVA Plus BCG Versus BCG Monotherapy In Participants With BCG-Naïve/BCG-Exposed High-Grade Non-Muscle Invasive Papillary Bladder Cancer | withdrawn | Phase 3 | 0 | ImmunityBio, Inc.INDUSTRY | 0 | May 19, 2026 | clinicaltrials |
| NCT02143804 | Safety and Efficacy of CG0070 Oncolytic Virus Regimen in Patients With High Grade Non-Muscle Invasive Bladder Cancer(exBOND) | withdrawn | Phase 2 | 0 | CG Oncology, Inc.INDUSTRY | 1 | Apr 2, 2026 | clinicaltrials |
| NCT05564416 | Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA Trial | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Oct 21, 2025 | clinicaltrials |
| NCT06422312 | A Study Comparing a Disposable Flexible Cystoscope With Reusable Scopes in Adult Patients. | withdrawn | N/A | 0 | Guangzhou Red Pine Medical Instrument Co., Ltd.INDUSTRY | 1 | Apr 4, 2025 | clinicaltrials |
| NCT06390111 | A Trial to Evaluate Efficacy of Reinduction With Nadofaragene Firadenovec in Subjects With CIS ± High-grade Ta/T1 and no Complete Response to First Nadofaragene Firadenovec Dose.(ABLE-42) | withdrawn | Phase 4 | 0 | Ferring PharmaceuticalsINDUSTRY | 1 | Nov 22, 2024 | clinicaltrials |
| NCT04583553 | Comparative Microbial Analysis of Cystitis in Non-muscle-invasive Bladder Cancer Patients Using Vikor Scientific Urine-ID Testing Menu (IDTM) and Standard Laboratory Culture(VS-UrineID) | withdrawn | — | 0 | University of Kansas Medical CenterOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT05846165 | InveStigAting Bladder fiELd-cycLing imAging(ISABELLA) | withdrawn | N/A | 0 | University of AberdeenOTHER | 0 | Oct 8, 2024 | clinicaltrials |
| NCT05655598 | TAS-116 Plus Palbociclib in Breast and Rb-null Cancer | withdrawn | Phase 1 | 0 | Brown UniversityOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06301308 | A Novel Application of 2% Lidocaine Injection for Male Rigid cycstoscopy-a Patient-blinded Randomised Trial | withdrawn | Phase 3 | 0 | Second Xiangya Hospital of Central South UniversityOTHER | 1 | Apr 24, 2024 | clinicaltrials |
| NCT03909893 | A Study of Adaptive Radiation Therapy for Pelvic Genitourinary Cancer(ARTGU) | withdrawn | N/A | 0 | University Health Network, TorontoOTHER | 1 | Mar 19, 2024 | clinicaltrials |
| NCT05335707 | Longitudinal Geriatric Assessment to Optimize Outcomes of Older Patients With Muscle-Invasive Bladder Cancer After Radical Cystectomy | withdrawn | — | 0 | University of Kansas Medical CenterOTHER | 0 | Feb 28, 2024 | clinicaltrials |
| NCT04602117 | ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer | withdrawn | Phase 1 | 0 | QuantumLeap Healthcare CollaborativeOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT04054752 | Vaccine Response With NT-I7 | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 1 | Nov 2, 2023 | clinicaltrials |
| NCT05120622 | Trial of Local Cystoscopic Injection of Tremelimumab Plus Systemic Durvalumab for High Risk Non-Muscle Invasive Bladder Cancer(Rideau) | withdrawn | Phase 1 / Phase 2 | 0 | University of British ColumbiaOTHER | 1 | Oct 31, 2023 | clinicaltrials |
| NCT03552796 | sEphB4-HSA in Treating Participants With BCG-Unresponsive or Refractory Bladder Cancer | withdrawn | Phase 1 | 0 | University of Southern CaliforniaOTHER | 1 | Jun 26, 2023 | clinicaltrials |
| NCT05259397 | PF-07225570 Alone or in Combination With an Anti-PD-1 Antibody in Recurrent Non-muscle Invasive Bladder Cancer (NMIBC) | withdrawn | Phase 1 | 0 | PfizerINDUSTRY | 2 | Mar 8, 2023 | clinicaltrials |
| NCT04127318 | Low-moderate Intensity Pedaling During Immunotherapy Administration | withdrawn | N/A | 0 | Rush University Medical CenterOTHER | 1 | Sep 23, 2022 | clinicaltrials |
| NCT05395260 | FL- 101 Study in Non-Metastatic MIBC | withdrawn | Early Phase 1 | 0 | Flame BiosciencesINDUSTRY | 0 | Aug 19, 2022 | clinicaltrials |
| NCT04972253 | Phase I BLASST-3 Trial((BLASST)-3) | withdrawn | Phase 1 | 0 | Guru P. SonpavdeOTHER | 0 | Aug 10, 2022 | clinicaltrials |
| NCT03839472 | Continuous Bladder Irrigation Following Transurethral Resection of Bladder Tumors | withdrawn | N/A | 0 | Case Comprehensive Cancer CenterOTHER | 1 | May 11, 2022 | clinicaltrials |
| NCT05260788 | Mapping 3D Bladder | withdrawn | — | 0 | University Health Network, TorontoOTHER | 1 | Apr 14, 2022 | clinicaltrials |
| NCT04280640 | Relationship Between Circulating Tumor Cell Cultures' Treatment Response and Clinical Outcomes | withdrawn | — | 0 | UNC Lineberger Comprehensive Cancer CenterOTHER | 0 | Oct 18, 2021 | clinicaltrials |
| NCT04464967 | Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers | withdrawn | Phase 1 / Phase 2 | 0 | NKGen Biotech, Inc.INDUSTRY | 0 | May 12, 2021 | clinicaltrials |
| NCT02688348 | Quality of Life After Bladder-Preservation Chemotherapy and Radiation Therapy in Patients With Muscle-Invasive Bladder Cancer | withdrawn | N/A | 0 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 24, 2020 | clinicaltrials |
| NCT04073160 | TRIO Bladder: A Study of Durvalumab Plus Tremelimumab Followed by Concurrent Durvalumab Plus Bladder Radiation in Muscle-Invasive Bladder Cancer(TRIO Bladder) | withdrawn | Phase 1 | 0 | Daniel George, MDOTHER | 1 | Jul 7, 2020 | clinicaltrials |
| NCT03517995 | Randomized, Phase II Clinical Trial of Sulforaphane in Bladder Cancer Chemoprevention | withdrawn | Phase 2 | 0 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | May 28, 2020 | clinicaltrials |
| NCT04089163 | A Study of Toca 511 & Toca FC in Patients With Recurrent High Grade Non-Muscle Invasive Bladder Cancer (Toca 8) | withdrawn | Phase 1 | 0 | Tocagen Inc.INDUSTRY | 0 | Mar 30, 2020 | clinicaltrials |
| NCT03935347 | Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating Patients With Unresectable or Metastatic Transitional Cell Cancer Who Have Failed Cisplatin-Based Chemotherapy | withdrawn | Phase 2 | 0 | Roswell Park Cancer InstituteOTHER | 1 | Jan 2, 2020 | clinicaltrials |
| NCT04040725 | Rogaratinib for BCG Refractory High Risk Non-Muscle Invasive Bladder Cancer With FGFR1/2 Overexpression | withdrawn | Phase 2 | 0 | Dana-Farber Cancer InstituteOTHER | 0 | Dec 17, 2019 | clinicaltrials |
| NCT00880854 | Study of CP-675,206 in Bacillus Calmette-Guerin (BCG)-Resistant Bladder Cancer | withdrawn | Phase 1 | 0 | University of Wisconsin, MadisonOTHER | 0 | Nov 15, 2019 | clinicaltrials |
| NCT03298958 | Secondary Prevention Trial of Rapamycin in Patients With Resected Non-muscle Invasive Bladder Cancer | withdrawn | Phase 3 | 0 | The University of Texas Health Science Center at San AntonioOTHER | 1 | Jun 12, 2019 | clinicaltrials |
| NCT01060319 | A Comprehensive Study to Isolate Tumor-initiating Cells From Human Epithelial Malignancies | withdrawn | — | 0 | Stanford UniversityOTHER | 1 | Apr 18, 2019 | clinicaltrials |
| NCT02438852 | Continuous Infusion of Ropivacaine Hydrochloride in Reducing Pain After Surgery in Patients With Bladder Cancer | withdrawn | Phase 3 | 0 | University of Southern CaliforniaOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT03419130 | Radiation Therapy and Pembrolizumab in Treating Patients With Localized Urothelial Bladder Cancer | withdrawn | Phase 2 | 0 | University of California, San FranciscoOTHER | 1 | Dec 7, 2018 | clinicaltrials |
| NCT02471495 | RITE-EUROPE (Radiofrequency-Induced Thermochemotherapy Effect-EUROPE) | withdrawn | Phase 3 | 0 | Medical Enterprises Europe B.V.INDUSTRY | 0 | May 7, 2018 | clinicaltrials |
| NCT01710293 | Intervention Protocol for Automated Point-of-Care Surveillance of Outpatient Delays in Cancer Diagnosis(PACT CREATE 3) | withdrawn | N/A | 0 | VA Office of Research and DevelopmentFED | 1 | Feb 26, 2018 | clinicaltrials |
| NCT02845050 | Phase Ib/II Study Assessing the Neo-adjuvant Combination Therapy of Vinflunine With Cisplatin Followed by Radical Cystectomy in Patients With Muscle-invasive Bladder Cancer (JaNEO)(JaNEO) | withdrawn | Phase 1 / Phase 2 | 0 | Ligartis GmbHINDUSTRY | 1 | Feb 13, 2018 | clinicaltrials |
| NCT01826097 | Improving Sensitivity of Urine Cytology for Bladder Cancer | withdrawn | N/A | 0 | Johns Hopkins UniversityOTHER | 1 | Feb 1, 2018 | clinicaltrials |
| NCT02514408 | Circulating Tumor Cells in Operative Blood in Patients With Bladder Cancer | withdrawn | — | 0 | University of Southern CaliforniaOTHER | 0 | Jan 2, 2018 | clinicaltrials |
| NCT03238664 | Robot-Assisted Laparoscopic High-Intensity Focused Ultrasound and Radical Cystectomy for Thermal Ablation of Muscle Invasive Cells in Patients With Bladder Tumors | withdrawn | N/A | 0 | University of Southern CaliforniaOTHER | 0 | Jan 2, 2018 | clinicaltrials |
| NCT02944357 | Gemcitabine Hydrochloride, Cisplatin, and AGS-003-BLD in Treating Patients With Muscle-Invasive Bladder Cancer Undergoing Surgery | withdrawn | N/A | 0 | Mayo ClinicOTHER | 1 | Nov 17, 2017 | clinicaltrials |
| NCT03150836 | Radiation Therapy and Durvalumab, With or Without Tremelimumab, in Patients With Bladder Cancer | withdrawn | Phase 2 | 0 | Terence Friedlander, MDOTHER | 1 | Oct 19, 2017 | clinicaltrials |
| NCT03007771 | Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia | withdrawn | Phase 1 | 0 | Washington University School of MedicineOTHER | 0 | Oct 6, 2017 | clinicaltrials |
| NCT02252393 | Urinary Diversion During Robotic Assisted Radical Cystectomy in Patients With Bladder Cancer | withdrawn | N/A | 0 | Case Comprehensive Cancer CenterOTHER | 0 | Nov 9, 2016 | clinicaltrials |
| NCT02718742 | Paclitaxel Albumin-Stabilized Nanoparticle Formulation After Cisplatin-Based Chemotherapy and Surgery in Treating Patients With High-Risk Bladder Cancer | withdrawn | Phase 2 | 0 | Mayo ClinicOTHER | 1 | Apr 18, 2016 | clinicaltrials |
| NCT00785694 | Recurrence of Bladder Cancer After Transurethral Resection With Hexvix | withdrawn | Phase 4 | 0 | GE HealthcareINDUSTRY | 1 | Apr 24, 2015 | clinicaltrials |
| NCT01284205 | First Line Comparative Study of EN3348 (MCC) vs BCG in NMIBC | withdrawn | Phase 3 | 0 | Bioniche Life Sciences Inc.INDUSTRY | 1 | Aug 29, 2014 | clinicaltrials |
Data updated 4 days agoSource updated Sep 24, 2026source: clinicaltrials